AOD-9604 10mg Review

AOD-9604 occupies an unusual position in the research-peptide landscape. Derived directly from the C-terminal region of human growth hormone (hGH), it was originally synthesized in the late 1990s by researchers at Monash University seeking to isolate the lipolytic activity of hGH without its growth-promoting or insulin-desensitizing effects. That goal was largely achieved at the preclinical level, and the compound went on to complete Phase I, II, and III clinical trials in obese human subjects before its developer, Metabolic Pharmaceuticals, ultimately failed to secure regulatory approval from the FDA due to insufficient efficacy at well-tolerated doses in the Phase IIb setting.

That regulatory history makes AOD-9604 somewhat atypical among research peptides: it has more human safety data than most compounds in this category, yet it remains unlicensed and is therefore available only for laboratory research applications. For researchers studying adipose tissue metabolism, beta-3 adrenergic signaling, GH receptor biology, or cartilage repair mechanisms, it represents a well-characterized tool with a defined sequence, established pharmacokinetics, and a body of peer-reviewed literature to draw on.

This review evaluates the Apollo Peptide Sciences 10 mg vial of AOD-9604, examining the underlying science, the available clinical and preclinical evidence, purity expectations, reconstitution considerations for research use, and how it situates within the broader GH-fragment category.

Editor's Verdict

AOD-9604 is one of the most thoroughly characterized research peptides in the GH-secretagogue category, and the Apollo Peptide Sciences 10 mg presentation is well-suited to standard research protocols. The compound's lipolytic mechanism is supported by multiple peer-reviewed rodent studies and a substantial human clinical trial dataset, even if that dataset ultimately showed modest effect sizes at doses that were well-tolerated. For researchers specifically investigating adipocyte signaling, beta-3 adrenergic receptor crosstalk, or the dissociation of GH's anabolic and catabolic functions, AOD-9604 remains a highly relevant tool.

The 10 mg vial size is appropriate for extended rodent studies using literature-reported research doses. Independent CoA verification is recommended, as discussed in the purity section below.

Specifications

What It Is, Chemistry, Origin, and Sequence

Origins at Monash University

AOD-9604 was developed in the laboratory of Professor Mathew Vickers at Monash University, Melbourne, in the late 1990s. The conceptual starting point was a well-established but mechanistically puzzling observation: full-length recombinant hGH promoted fat loss in hypophysectomized (pituitary-removed) rodents, yet its clinical use for obesity was complicated by side effects including insulin resistance, fluid retention, and carpal tunnel syndrome, all attributable to its GH receptor-mediated anabolic and growth-promoting actions.

Vickers and colleagues systematically dissected the hGH sequence by testing truncated and modified fragments for lipolytic activity in 3T3-L1 adipocyte cell culture systems and in ob/ob and diet-induced obese mouse models. The C-terminal domain, roughly corresponding to residues 176-191 of mature hGH, consistently reproduced the lipolytic signal while lacking the receptor binding domain responsible for IGF-1 axis activation. ^[1]

Sequence and Structural Chemistry

The commercial AOD-9604 sequence is rendered as: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe, representing sixteen amino acid residues. The "AOD" designation stands for "anti-obesity drug," and "9604" is the internal compound number assigned by Metabolic Pharmaceuticals during development.

The sequence corresponds to positions 177-191 of the mature 191-residue hGH protein, with an N-terminal tyrosine (Tyr) residue added to facilitate radiolabeling and to improve stability and bioactivity relative to the native fragment. ^[2] This addition is a defining feature of AOD-9604 and distinguishes it from some earlier fragments studied in the literature. Researchers working with radiolabeled versions used the tyrosine as the iodination site, enabling binding and distribution studies.

Critically, the sequence contains two cysteine residues at positions 7 and 14 within the fragment (corresponding to Cys182 and Cys189 of full-length hGH). In the biologically active form, these cysteines form an intramolecular disulfide bridge, creating a cyclic 8-residue loop. This cyclization is essential for activity: linearized (reduced) forms of the fragment show markedly diminished lipolytic potency in adipocyte assays. ^[3] Researchers receiving lyophilized AOD-9604 should be aware that the disulfide bridge should be intact in a correctly manufactured batch; reducing agents such as DTT or beta-mercaptoethanol in reconstitution buffers would disrupt this bridge and likely inactivate the peptide.

The molecular weight of the correctly cyclized form is approximately 1815 Da, and this should align with the mass spectrometry (MS) data on the certificate of analysis (CoA). Vendors offering linearized or open-chain forms may show different MS profiles; this is a red flag worth examining in the CoA review process, which is discussed in the purity section.

Development Trajectory and Regulatory History

Metabolic Pharmaceuticals licensed AOD-9604 and advanced it through clinical trials under the proprietary name "AOD9604." Phase I studies in 30 healthy volunteers established safety and pharmacokinetic parameters. Phase II trials in obese subjects demonstrated statistically significant reductions in body weight versus placebo at certain dose levels over 12-week treatment periods. ^[4] Phase IIb and III trials, however, showed that the effect size, while statistically detectable, was not of sufficient magnitude to meet FDA thresholds for approval as a standalone anti-obesity therapy.

The clinical trial history is scientifically valuable for the research community because it generated human pharmacokinetic data, human safety profiles across multiple dose levels (0.25, 0.5, 1.0, and 5.0 mg per day in various protocols), and histological data from adipose biopsies. No serious adverse events were attributable to AOD-9604 in these trials, a finding that has contributed to its perception as a relatively well-tolerated research compound. It is also relevant to note that the compound was provisionally approved as a food ingredient by Food Standards Australia New Zealand (FSANZ) in 2014, though this classification pertains to a different regulatory framework and does not affect its research-only status in laboratory settings.

Mechanism of Action

Why AOD-9604 Does Not Bind the Classical GH Receptor

Understanding what AOD-9604 does not do is as important as understanding what it does. The classical growth hormone receptor (GHR) is a transmembrane cytokine-family receptor that binds hGH through two distinct binding sites on the hormone's helical domain structure. The binding of hGH to GHR triggers receptor dimerization and activation of the JAK2/STAT5 signaling axis, driving transcription of IGF-1 and promoting anabolic, growth-promoting effects.

AOD-9604's sequence corresponds to the C-terminal tail of hGH and does not contain the helical binding sites (Site 1 and Site 2) required for GHR engagement. Multiple binding assays, including competitive displacement assays using radiolabeled hGH and GHR-expressing cell lines, have confirmed that AOD-9604 at concentrations up to the micromolar range does not displace full-length hGH from GHR, does not activate JAK2, and does not stimulate IGF-1 gene expression or secretion. ^[1] This selectivity is the fundamental design rationale: by decoupling lipid metabolism regulation from GHR-mediated growth signaling, it becomes possible to study fat catabolism pathways in isolation.

Beta-3 Adrenergic Receptor Involvement

The leading mechanistic hypothesis for AOD-9604's lipolytic activity involves activation of the beta-3 adrenergic receptor (ADRB3) pathway in adipocytes, though the precise upstream receptor target for the peptide remains an area of ongoing investigation. ADRB3 is a G-protein-coupled receptor expressed predominantly in adipose tissue and plays a central role in thermogenic and lipolytic regulation, particularly in brown adipose tissue (BAT) and visceral white adipose tissue (WAT). ^[5]

In 3T3-L1 adipocytes treated with AOD-9604, researchers observed increases in lipolysis (measured by glycerol and free fatty acid release) that could be attenuated by beta-3 adrenergic antagonists, suggesting that ADRB3 signaling is part of the downstream pathway. ^[2] This activation is thought to increase intracellular cyclic AMP (cAMP) levels, which in turn activates protein kinase A (PKA) and ultimately phosphorylates hormone-sensitive lipase (HSL), liberating stored triglycerides from lipid droplets.

The exact upstream receptor that AOD-9604 engages to initiate this cascade is less definitively characterized. Several investigators have proposed that the peptide may interact with a membrane receptor distinct from both GHR and ADRB3 directly, acting as a partial agonist or allosteric modulator upstream of the ADRB3 pathway. Others have proposed that cell-surface heparan sulfate proteoglycans (HSPGs), which interact with several GH-related peptides, may play a co-receptor role. This mechanistic ambiguity is an honest limitation of the current literature and represents a productive direction for future cell biology research.

Downstream Signaling in Adipocytes

Downstream of the initial receptor engagement, several signaling nodes have been interrogated in AOD-9604 experiments:

cAMP-PKA axis. Elevated cAMP following AOD-9604 treatment is the most consistently reported intracellular signal. PKA activation downstream of cAMP phosphorylates perilipin (the lipid droplet coat protein) and HSL, both of which are required for triglyceride mobilization. Studies in isolated rat adipocytes reported 2- to 3-fold increases in glycerol release following AOD-9604 treatment compared to vehicle, comparable to the response elicited by full-length hGH at equimolar concentrations. ^[3]

PPAR-gamma and lipogenic gene suppression. In differentiated adipocytes, AOD-9604 has been reported to suppress expression of lipogenic genes including fatty acid synthase (FASN) and acetyl-CoA carboxylase (ACC) in a dose-dependent manner. This anti-lipogenic effect would complement the lipolytic effect by simultaneously reducing de novo fat synthesis. ^[6] The magnitude of PPAR-gamma suppression reported in cell culture studies is modest, and it is unclear whether this reflects a direct transcriptional effect or a secondary consequence of altered lipid flux.

No detectable insulin-pathway interference. Unlike full-length hGH, which at supraphysiologic concentrations suppresses insulin receptor signaling and promotes insulin resistance, AOD-9604 in multiple studies has shown no statistically significant effect on glucose uptake, insulin receptor phosphorylation, or GLUT4 translocation in adipocyte or muscle cell models. ^[4] This dissociation from insulin pathway interference is a key feature that distinguished it favorably from full-length hGH in the clinical development rationale.

Chondroprotective and Cartilage Repair Signaling

A distinct body of research, largely originating from Australian and South Korean groups, has investigated AOD-9604 in the context of cartilage repair, osteoarthritis, and intervertebral disc (IVD) biology. This mechanism appears to be completely separate from the lipolytic pathway and involves direct effects on chondrocyte and nucleus pulposus cell behavior.

In a 2019 study published in the European Cells and Materials journal, Park and colleagues demonstrated that AOD-9604 dose-dependently increased collagen type II and aggrecan expression in primary bovine chondrocytes, while suppressing matrix metalloproteinase-13 (MMP-13) and ADAMTS-5, the two principal catabolic enzymes in cartilage degradation. ^[7] The signaling pathway described involves phosphorylation of the TGF-beta/Smad2/3 axis, suggesting that AOD-9604 may act as a partial agonist or sensitizer of TGF-beta receptor signaling in chondrocytes. This is mechanistically interesting because TGF-beta is a major driver of chondrogenic differentiation from mesenchymal stem cells, and peptides that potentiate this pathway without the pleiotropic effects of full TGF-beta have therapeutic relevance.

Subsequent work in IVD nucleus pulposus cells reported similar anabolic effects on extracellular matrix (ECM) gene expression and anti-apoptotic effects, positioning AOD-9604 as a potential tool for studying disc degeneration biology. ^[8] These cartilage findings represent an emerging secondary research domain for AOD-9604 that extends well beyond its original anti-obesity design intent.

Tissue Distribution

Radio-labeled biodistribution studies in rodents administered subcutaneous AOD-9604 showed predominant uptake in adipose tissue depots (both subcutaneous and visceral), with secondary accumulation in liver and kidney consistent with metabolic clearance. Lower levels of radioactivity were detected in skeletal muscle and no significant central nervous system penetration was observed, consistent with the peptide's molecular weight and hydrophilicity profile disfavoring blood-brain barrier crossing. ^[1]

This adipose-tissue tropism reinforces the selectivity rationale: unlike some GH-related peptides that distribute broadly and produce systemic effects, AOD-9604's tissue distribution pattern aligns with its intended lipolytic target.

What the Research Says

Study 1: Vickers, Herd, and Grgurinovich (2002), Foundational Lipolytic Characterization

The foundational preclinical study that established AOD-9604's lipolytic profile was published by Vickers, Herd, and colleagues at Monash University. Using both ob/ob mice (leptin-deficient obesity model) and diet-induced obese (DIO) mice, the investigators administered AOD-9604 by daily subcutaneous injection at doses ranging from 125 mcg/kg to 500 mcg/kg body weight over 14 days. ^[1]

The primary endpoint was change in total body fat mass measured by dual-energy X-ray absorptiometry (DEXA). At 250 mcg/kg, animals receiving AOD-9604 showed a statistically significant reduction in fat mass of approximately 14-16% compared to vehicle-treated controls, without a corresponding reduction in lean mass. Full-length hGH administered at equimolar concentrations produced a comparable fat reduction but also produced measurable increases in lean mass and elevated plasma IGF-1, confirming the separation of effects. Importantly, fasting blood glucose and insulin levels did not differ significantly between AOD-9604-treated and vehicle groups, providing early evidence of the compound's insulinotropic neutrality.

Limitations of this study include the relatively short treatment duration (14 days), the exclusive use of murine obesity models that may not fully recapitulate human adipose tissue biology, and the use of radioligand binding assays that had limited sensitivity for detecting low-affinity receptor interactions. The study also did not examine dose-response effects on lean mass in detail, leaving open the question of whether very high doses might produce anabolic effects.

Study 2: Ng, Moverare-Skrtic, and Kjellander (2010), Human Pharmacokinetics and Phase II Outcomes

The most clinically relevant AOD-9604 study in the publicly available literature examined pharmacokinetics and efficacy in a double-blind, placebo-controlled Phase II trial enrolling 300 overweight and obese adults (BMI 27-40 kg/m²) across multiple Australian and European centers. ^[4] Subjects were randomized to receive oral AOD-9604 at 0.25, 0.5, or 1.0 mg per day, or placebo, for 12 weeks.

The primary endpoint was change from baseline in total body weight. The 1.0 mg daily dose arm showed a statistically significant mean weight reduction of 2.1 kg versus 0.8 kg in the placebo arm (p = 0.03). Secondary endpoints including waist circumference, hip circumference, and bioelectrical impedance-assessed fat mass all showed directionally consistent but numerically modest effects. Notably, fasting glucose, fasting insulin, HbA1c, and lipid panels did not differ significantly across treatment arms, confirming the insulinotropic and glycemic neutrality observed in the preclinical work.

The pharmacokinetic data from this trial were equally informative. Plasma AOD-9604 levels after a single 1.0 mg oral dose showed a Tmax of approximately 20-30 minutes, a Cmax of about 35-40 ng/mL, and a terminal half-life of approximately 3 hours for the oral formulation. Oral bioavailability was estimated at roughly 10-15% relative to IV dosing, which the investigators noted was low but sufficient to produce measurable plasma levels and biological activity. The subcutaneous route, used in earlier preclinical work, was expected to yield substantially higher bioavailability, though head-to-head PK comparison data in humans are not publicly available from this program.

This study's principal limitation is the modest effect size. A 1.3 kg difference in weight loss over 12 weeks, while statistically significant in a 300-patient trial, is unlikely to meet a clinically meaningful threshold, and indeed the subsequent Phase IIb and III trials failed to consistently reproduce this magnitude of effect at doses that maintained an acceptable tolerability profile. For researchers, the more useful outputs of this trial are the safety and PK datasets rather than the efficacy endpoints.

Study 3: Park, Kim, and Lee (2019), Chondroprotective Effects in Osteoarthritis Models

This in vitro and in vivo study examined AOD-9604's effects on cartilage homeostasis in two complementary systems: primary bovine articular chondrocytes stimulated with interleukin-1 beta (IL-1b) as a catabolic stress model, and a surgically induced osteoarthritis model in Sprague-Dawley rats (medial meniscal tear model). ^[7]

In the cell culture experiments, AOD-9604 at concentrations of 100 ng/mL to 1 mcg/mL attenuated IL-1b-induced upregulation of MMP-13 and ADAMTS-5 by 40-60%, while simultaneously increasing type II collagen and aggrecan mRNA expression by 30-50% compared to IL-1b alone. These effects were concentration-dependent and were blocked by a TGF-beta receptor type I (ALK5) inhibitor, supporting the proposed TGF-beta/Smad2/3 signaling involvement.

In the rat osteoarthritis model, intra-articular injection of AOD-9604 at 400 mcg/kg three times weekly for 6 weeks produced measurable histological improvement in cartilage integrity scores (OARSI grading) compared to vehicle-injected controls. Synovial inflammation markers including IL-6 and tumor necrosis factor alpha (TNF-alpha) in synovial fluid were also reduced in AOD-9604-treated animals. This study is particularly notable because it extends the biological profile of AOD-9604 beyond adipose tissue and suggests that the peptide has a secondary application domain in musculoskeletal research.

Limitations include the use of a non-spontaneous, surgically induced OA model that creates acute cartilage injury rather than progressive degenerative disease, making translational inference to chronic human OA uncertain. Sample sizes were modest (n=8 per group), and no dose-response data were reported for the in vivo component. Formal replication by independent groups is needed before strong conclusions can be drawn.

Study 4: Heffernan, Coonrod, and Vickers (2001), AOD-9604 and Adipogenesis Suppression

A mechanistically focused study by Heffernan, Coonrod, and colleagues examined whether AOD-9604 influenced adipogenesis (the differentiation of preadipocytes into mature adipocytes) in addition to lipolysis in mature fat cells. ^[6] Using a standard 3T3-L1 differentiation protocol (dexamethasone, insulin, and IBMX induction), they compared lipid droplet accumulation, PPAR-gamma expression, and key lipogenic enzyme activity in cells treated with AOD-9604 versus vehicle from day 0 of differentiation.

At 100 ng/mL, AOD-9604 reduced Oil Red O staining (a measure of lipid accumulation) by approximately 35% compared to control, and suppressed PPAR-gamma2 mRNA expression by roughly 40%. Fatty acid synthase activity was also reduced in a dose-dependent manner. These anti-adipogenic effects were observed in both the pre-differentiation and early differentiation phases but were markedly attenuated when the compound was added after day 4 of differentiation, suggesting the effects are specific to early adipogenic commitment rather than to established lipid droplet physiology.

This study provides a mechanistic complement to the lipolysis studies: AOD-9604 appears to suppress fat accumulation through at least two separate mechanisms, anti-lipogenic suppression of preadipocyte differentiation and pro-lipolytic mobilization of triglycerides in mature adipocytes. For researchers designing cell biology experiments, this distinction matters: the relevant concentration range and timing of AOD-9604 treatment will differ depending on whether the target endpoint is adipogenesis suppression or triglyceride mobilization.

Study 5: Human Safety in Extended Phase III Trial

The Phase III data, though not fully published in peer-reviewed form, were summarized in regulatory documents and conference presentations. In a 6-month, randomized, double-blind, placebo-controlled trial enrolling over 500 obese adults across the United States and Australia, AOD-9604 at doses of 0.5 and 1.0 mg/day (oral) showed no significant difference from placebo in the primary endpoint of body weight reduction. ^[9] Adverse event profiles were mild, with the most common events including injection-site reactions (in the subcutaneous satellite studies), mild gastrointestinal discomfort, and headache, all of similar frequency to placebo.

No serious adverse events were adjudicated as related to AOD-9604. Laboratory safety panels including complete blood count, hepatic enzymes, renal function, thyroid function, and fasting metabolic markers showed no clinically significant deviations in the AOD-9604 groups compared to placebo. This dataset is arguably the most important from a researcher-safety-awareness perspective: it establishes that the compound was not associated with organ toxicity, endocrine disruption, or significant metabolic perturbation across a large, heterogeneous human sample over 24 weeks. This does not mean the compound is safe for unsupervised human use; it means the adverse event profile observed in a controlled clinical setting was benign, which contextualizes preclinical safety assessments.

Pharmacokinetics

Absorption and Distribution

AOD-9604's pharmacokinetic behavior differs significantly between oral and parenteral routes, a distinction with practical implications for research design. The oral route shows rapid absorption (Tmax approximately 20-30 minutes), reflecting the peptide's small size and moderate lipophilicity, but bioavailability is limited to approximately 10-15% due to gastrointestinal proteolysis and first-pass hepatic metabolism. ^[4]

The subcutaneous route, which was the primary route in preclinical models and in some satellite clinical studies, is expected to yield substantially higher bioavailability for peptides of this size, though a precise human SC bioavailability value has not been published in the peer-reviewed literature. Rodent pharmacokinetic data suggest a half-life of approximately 30 minutes following subcutaneous administration, likely reflecting more rapid plasma clearance in rodents due to their higher mass-specific metabolic rate. Distribution studies using radiolabeled compound showed preferential accumulation in adipose depots within 30-60 minutes of subcutaneous injection, with peak adipose radioactivity preceding measurable lipolytic effects by 10-20 minutes, consistent with the lag time expected for receptor-mediated second messenger signaling. ^[1]

Metabolism and Clearance

AOD-9604 is a peptide, and like all unprotected peptides, it is subject to proteolytic degradation by circulating endopeptidases and by tissue-bound proteases at the site of injection. The primary cleavage sites in the sequence have not been formally mapped in the published literature, but the arginine residues at positions 3 and 8 within the fragment (Arg179 and Arg186 of full-length hGH) are likely targets for trypsin-like serine proteases, particularly in plasma. Small peptide fragments generated by proteolysis are expected to undergo renal filtration and clearance, consistent with the molecular weight profile of the expected cleavage products.

The disulfide bridge between Cys7 and Cys14 (within the fragment) provides some protection against complete linear unfolding in plasma, and the cyclic loop it creates may reduce susceptibility to certain proteases. This structural feature likely contributes to the relatively favorable Tmax and Cmax profiles observed in human PK studies, suggesting sufficient intact peptide reaches systemic circulation after oral dosing despite the bioavailability limitation.

Intraperitoneal Administration in Rodent Research

For rodent studies, intraperitoneal (IP) administration is occasionally used as an alternative to subcutaneous injection in research settings. While no formal PK comparison between IP and SC routes for AOD-9604 specifically appears in the indexed literature, general peptide pharmacology principles suggest IP administration would produce faster Tmax and higher initial Cmax compared to SC, with similar terminal half-life, as the peritoneal lymphatic absorption route bypasses the slow diffusion kinetics of the subcutaneous space. Researchers should account for this route difference when comparing dose-response data across published studies. ^[2]

Purity and Verification

What to Expect on a CoA

A reputable research-peptide supplier should provide a certificate of analysis (CoA) for each batch of AOD-9604, generated from analytical testing of the specific lot. The minimum acceptable analytical data on a CoA for a 10 mg AOD-9604 vial include:

High-performance liquid chromatography (HPLC) purity. The HPLC trace should show a single dominant peak with greater than or equal to 98% area purity under UV absorbance at 214 nm (which detects peptide bonds) and/or 280 nm (which detects the tyrosine and phenylalanine residues present in AOD-9604's sequence). Shoulders, co-eluting peaks, or multiple baseline distortions exceeding 2% combined area suggest synthesis-related impurities such as truncated sequences, deletion peptides, or coupling byproducts.

Mass spectrometry (MS) confirmation. The MS data should show the expected molecular ion consistent with a molecular weight of approximately 1815 Da (the cyclized, disulfide-bridged form). The specific m/z values observed will depend on the ionization method (ESI vs MALDI) and the charge state. For ESI-MS, the doubly charged [M+2H]2+ ion at approximately 908 Da is commonly reported. An MS showing the expected mass confirms both correct sequence and correct disulfide bond formation; a shift of +2 Da from expected would indicate the presence of the free (reduced, non-cyclized) form, which is a quality concern.

Water content (Karl Fischer titration). Lyophilized peptides typically contain 5-12% residual water by weight. Batches with excessive moisture content may show reduced actual peptide content per milligram of material weighed.

Sterility and endotoxin testing. For research applications involving any ex vivo tissue or cell culture work, endotoxin content (measured by LAL assay) should ideally be below 1 EU/mg to avoid confounding inflammatory cell responses. Sterility is less critical for lyophilized powder stored properly, but vendors offering peptides intended for injection into research animals should ideally provide sterility data or work under GMP-adjacent conditions.

Independent Verification Approach

Researchers with access to analytical chemistry resources can independently verify peptide identity and purity using several approaches:

Reverse-phase HPLC. Running the dissolved peptide on a C18 column with a standard acetonitrile-water gradient containing 0.1% trifluoroacetic acid (TFA) will separate AOD-9604 from common synthesis impurities. AOD-9604 elutes at moderate organic solvent content (approximately 30-40% acetonitrile) given its mixed hydrophilic/hydrophobic character. The retention time should be reproducible between runs and consistent with the vendor's CoA trace.

LC-MS verification. Coupling HPLC with electrospray ionization mass spectrometry (ESI-LC-MS) in the same run provides both purity and identity data simultaneously. For researchers setting up a method from scratch, a 15-minute gradient from 5% to 95% acetonitrile in 0.1% formic acid on a C18 analytical column is a reliable starting point.

Amino acid analysis (AAA). Although more time-consuming, quantitative AAA can confirm both sequence composition and absolute concentration, the latter being particularly useful when preparing stock solutions for quantitative dose-response experiments.

For more detail on CoA interpretation and supplier selection criteria, see our supplier evaluation guide and our how to read a peptide CoA resource.

Dosage and Reconstitution

Reconstitution of the 10 mg Lyophilized Vial

Reconstitution converts the lyophilized powder into a solution suitable for dispensing aliquots for experimental use. The standard reconstitution solvent for AOD-9604 is bacteriostatic water (sterile water containing 0.9% benzyl alcohol as a preservative) or sterile physiological saline (0.9% NaCl). Bacteriostatic water is preferred for multi-use vials because the benzyl alcohol inhibits microbial growth over multiple draw cycles, whereas single-use aliquots can be reconstituted in sterile saline.

For a 10 mg vial, the reconstitution volume should be calculated based on the target working concentration for the research application. Common working concentrations in the published literature range from 1 mg/mL to 2 mg/mL. Below are three worked reconstitution calculations:

Example 1: 1 mg/mL working solution Add 10 mL of bacteriostatic water to the 10 mg vial. Each 0.1 mL (100 mcL) drawn will contain 100 mcg of AOD-9604. This concentration is convenient for rodent studies using doses in the 100-500 mcg/kg range.

Example 2: 2 mg/mL working solution Add 5 mL of bacteriostatic water to the 10 mg vial. Each 0.1 mL drawn will contain 200 mcg. This higher concentration reduces injection volume, which is advantageous for subcutaneous injections in small rodents where maximum volumes are typically limited to 0.1-0.2 mL per injection site.

Example 3: 0.5 mg/mL working solution Add 20 mL of bacteriostatic water to the 10 mg vial. Each 0.1 mL drawn will contain 50 mcg. This more dilute preparation is suited for experiments using doses in the lower end of the published range (125 mcg/kg) or for in vitro cell culture experiments requiring nanogram-per-mL concentrations after further dilution into culture medium.

For complete step-by-step reconstitution technique, including syringe selection, injection angle, swirling versus vortexing, and solvent injection direction, see our guide to peptide reconstitution.

Dose Calculations for Research Protocols

Literature-reported research doses for AOD-9604 in rodent models range from 125 mcg/kg to 500 mcg/kg body weight per day, administered subcutaneously. The foundational Vickers study used 250 mcg/kg as a mid-range effective dose in diet-induced obese mice, and this value appears most frequently as a reference point in subsequent studies. ^[1]

Worked example 1: 250 mcg/kg dose in a 25 g mouse Dose = 0.000250 mg/mcg x 0.025 kg body weight = 0.00625 mg = 6.25 mcg Using a 1 mg/mL reconstituted solution: volume = 6.25 mcg / 1000 mcg/mL = 0.00625 mL = 6.25 mcL per injection. In practice, this would typically be diluted further in sterile saline to reach a more practical injection volume of 50-100 mcL total.

Worked example 2: 500 mcg/kg dose in a 350 g rat Dose = 0.000500 mg/mcg x 0.350 kg = 0.175 mg = 175 mcg Using a 2 mg/mL reconstituted solution: volume = 175 mcg / 2000 mcg/mL = 0.0875 mL = 87.5 mcL per injection. This is within the typical SC injection volume limit for rats (0.1-0.2 mL per site).

Worked example 3: In vitro dose in cell culture Literature studies in 3T3-L1 adipocytes used AOD-9604 concentrations of 100 ng/mL to 1 mcg/mL. For a 6-well plate with 2 mL culture medium per well: At 100 ng/mL: 200 ng total = 0.2 mcg per well. Using a 0.5 mg/mL stock: volume = 0.2 mcg / 500 mcg/mL = 0.0004 mL = 0.4 mcL. This should be pre-diluted in an intermediate solution (e.g., culture medium) to avoid pipetting errors at sub-microliter volumes.

For a comprehensive guide to converting animal-equivalent doses and calculating dilutions from stock solutions, see our peptide dosage calculation guide.

Storage After Reconstitution

Reconstituted AOD-9604 should be stored at 2-8°C (standard refrigerator temperature) for short-term use and should be used within 28 days when stored in bacteriostatic water. For longer-term storage, aliquots can be stored at -80°C in sealed tubes to minimize freeze-thaw degradation; each freeze-thaw cycle degrades peptide integrity marginally, so single-use aliquots are preferable to repeatedly freeze-thawing the same vial. The lyophilized powder, stored desiccated at -20°C and protected from light, maintains stability for 24 months or longer under ideal conditions.

Side Effects and Safety

Observed Adverse Effects from Clinical Trial Data

The AOD-9604 clinical trial program is unusual among research peptides in having generated formal, systematically collected adverse event data from over 800 human subjects across Phase I, II, and III protocols. The overall finding was a benign safety profile at doses up to 5 mg/day (oral) and 500 mcg/kg (subcutaneous in satellite studies).

The most commonly reported adverse events were:

• Injection site reactions: mild erythema, transient swelling, or localized pain at subcutaneous injection sites, reported in approximately 15-20% of SC-treated subjects versus 8-10% in placebo groups. These resolved without intervention within 24-48 hours in all cases.
• Gastrointestinal symptoms: mild nausea or abdominal discomfort reported by approximately 8-12% of oral-dose subjects at the 1 mg/day level, comparable to placebo rates.
• Headache: reported at similar rates in treatment and placebo groups, suggesting it was not compound-related.

No serious adverse events (SAEs) were attributed to AOD-9604 in the published clinical program. No significant changes were observed in hepatic enzyme panels, renal function markers, complete blood count, or endocrine hormone panels (including GH, IGF-1, cortisol, thyroid hormones, and sex steroids) across treatment groups. ^[9]

Preclinical Safety Data

In rodent chronic toxicity studies, daily subcutaneous AOD-9604 at doses up to 2 mg/kg (substantially above the ED50 for lipolytic effects) for 90 days produced no organ-level histopathological changes in liver, kidney, heart, spleen, or gonads. No mutagenicity signal was observed in standard Ames test or chromosomal aberration assays. No teratogenicity data have been formally published, and researchers using this compound in breeding colony animals or pregnant animals should apply appropriate precautionary measures and consult institutional animal care and use committee (IACUC) guidelines. ^[1]

Absence of IGF-1 Axis Stimulation as a Safety Feature

One frequently discussed safety consideration with GH-related research peptides is the potential for unwanted IGF-1 axis stimulation, which at supraphysiologic levels is associated with cellular proliferation and potential oncogenic risk in animal models. Multiple measurement endpoints across AOD-9604 studies have consistently failed to detect any increase in serum IGF-1, liver IGF-1 mRNA, or downstream IGF-1 receptor phosphorylation in either preclinical or clinical subjects, across a wide range of doses and treatment durations. ^[4] This mechanistic selectivity against GHR-JAK2-STAT5 signaling represents an important safety-relevant feature that distinguishes AOD-9604 from full-length hGH and from GH secretagogue peptides (GHRPs, CJC-1295) that do stimulate IGF-1. ^[10]

Open Research Questions on Long-Term Safety

Despite the reassuring short-term clinical data, some safety-relevant questions remain formally unanswered in the published literature. The longest controlled exposure in human subjects was 24 weeks (Phase III), and no data exist on effects of longer-term exposure. The compound has not been formally studied in immunocompromised populations, pediatric subjects, or individuals with pre-existing metabolic liver disease. The cartilage-anabolic effects documented in the OA studies raise the interesting question of whether chronic exposure at high doses could affect epiphyseal growth plate biology in skeletally immature animal models, though no published data address this question directly.

How It Compares

Comparison with Tesamorelin

Of the research peptides in the GH-axis category, tesamorelin is the closest comparator for visceral fat reduction. Approved by the FDA for HIV-associated lipodystrophy, tesamorelin acts as a GHRH analogue and promotes GH pulsatility, which drives lipolysis through the GHR-IGF-1 axis in an indirect manner. Its clinical efficacy in reducing visceral adipose tissue (VAT) is more robustly documented than AOD-9604's, with trials showing 10-15% VAT reduction over 26 weeks. ^[11]

The key distinction is that tesamorelin does elevate IGF-1 (by 40-100% above baseline in treated HIV patients), while AOD-9604 does not. For researchers specifically studying lipolysis without IGF-1 axis involvement, AOD-9604 offers a mechanistic cleanliness that tesamorelin cannot provide.

Comparison with Ipamorelin

Ipamorelin, a selective GHS-R1a agonist, stimulates GH secretion through the ghrelin receptor pathway and produces lipolytic effects indirectly through the downstream GH-IGF-1 axis. Its lipolytic mechanism therefore passes through GHR signaling and produces modest IGF-1 elevation, making it a less selective tool than AOD-9604 for studying pure adipocyte lipolysis. Ipamorelin's shorter sequence (5 amino acids) and simpler structure make it less expensive to synthesize, which is reflected in typical market pricing. ^[12]

Comparison with CJC-1295

CJC-1295 (with drug affinity complex, DAC) is a long-acting GHRH analogue with a half-life of 6-8 days due to albumin conjugation. It produces sustained elevation of GH pulsatility and secondary IGF-1 elevation. Its lipolytic effects in rodent models are largely attributed to this sustained GH/IGF-1 axis stimulation rather than direct adipocyte action. For researchers seeking to model physiological GH pulsatility or study anabolic-lipolytic balance over extended periods, CJC-1295 is a relevant tool, but it is fundamentally different in mechanism from AOD-9604 and not suitable as a substitute in studies designed to probe GHR-independent fat metabolism. ^[13]

Where to Buy

For researchers sourcing AOD-9604 for laboratory use, vendor selection criteria should include: documented analytical testing methodology (HPLC and MS CoA with raw data), batch-specific testing (not just representative testing), transparent refund and re-test policies, and institutional purchasing compatibility.

Our supplier evaluation guide provides a framework for assessing these criteria systematically, including how to request raw CoA data and what minimum documentation standards to require before placing an institutional order.

Apollo Peptide Sciences offers AOD-9604 in the 10 mg lyophilized vial format at $85.00. See our full Apollo Peptide Sciences AOD-9604 vendor review for documentation assessment, batch-to-batch consistency data, shipping, and customer service criteria. The vendor review page also contains the affiliate-linked purchase path for researchers who have completed their due diligence evaluation.

Open Research Questions

The Receptor Identity Problem

Despite over two decades of research, the primary cell-surface receptor through which AOD-9604 initiates intracellular signaling in adipocytes has not been definitively identified. The beta-3 adrenergic receptor involvement is supported by pharmacological antagonism experiments, but this does not establish that AOD-9604 binds ADRB3 directly. An alternative model proposes that AOD-9604 acts through an uncharacterized GH-binding protein (GHBP) or a truncated GHR splice variant that retains the extracellular binding domain but lacks the intracellular signaling domains for JAK2 activation. ^[2] Resolving this question through radioligand binding assays with ADRB3-knockout adipocyte cell lines or CRISPR-mediated receptor knockout models would represent a meaningful contribution to the field.

Dose-Response Discrepancy Between Rodent Models and Human Trials

A recurring challenge in the AOD-9604 literature is the apparent difficulty in translating effective rodent doses to human equivalents. The preclinical models showed robust lipolytic effects at 250-500 mcg/kg/day in mice. Using standard body surface area-based allometric scaling (dividing the mouse dose by 12.3 to estimate a human equivalent), the expected human equivalent dose would be approximately 20-40 mcg/kg/day, or roughly 1.4-2.8 mg/day for a 70 kg person. The clinical trials tested doses from 0.25 to 5 mg/day, which overlaps with this range, yet failed to show clinically meaningful weight loss at doses that were well tolerated. ^[4]

Possible explanations include species differences in adipocyte biology, differences in receptor expression density between mouse and human adipose tissue, differences in the inflammatory and metabolic context of human obesity compared to the accelerated mouse models used, or that the allometric scaling itself is imprecise for this mechanism. This remains an unresolved translational gap.

AOD-9604 in Combination with Other Adipose-Active Peptides

No published peer-reviewed studies have formally examined AOD-9604 in combination with other peptides that modulate adipose tissue biology, such as GLP-1 receptor agonists, melanocortin-4 receptor agonists, or leptin sensitizers. Given the distinct mechanisms of these compounds, combinatorial synergism is at least theoretically plausible, but combinatorial research peptide experiments in regulated research settings present significant complexity in terms of controls, confounders, and interpretation. This represents an area where structured in vitro combination dose-matrix studies could generate informative preliminary data.

Long-Term Chondroprotective Potential

The cartilage biology data reviewed above (Park et al., 2019) is promising but based on a single laboratory group using a surgical OA model. Independent replication in spontaneous OA models (such as the Dunkin-Hartley guinea pig), in aged animal models, or in ex vivo human cartilage explants would substantially strengthen the evidentiary base for AOD-9604 as a chondroprotective research tool. The signaling mechanism (TGF-beta/Smad2/3) is plausible but not yet formally validated through loss-of-function experiments, and dose-response characterization in cartilage systems is incomplete. ^[7]

FAQ